Hiv Lifespan

Men and women receive a combination therapy highly active antiretroviral therapy, or HAART. It can reduce the incidence of opportunistic infections, delay the onset of AIDS, and increase lifetime. There is little doubt that HAART is beneficial for people living with HIV.

However, there are many unanswered questions about HAART. This is particularly true for women on HAART, the prevalence of HIV and AIDS in the male population is much higher. Because of this higher prevalence, more data are available on the effects of therapy for men than for women. As with any new treatment, we must take care to check their health with their doctor. If you are a woman who is HIV positive, these tips may help you and your health care provider to monitor your treatment and the effects it has on your health.

Therapeutic drug monitoring

The appropriate dose of drugs varies from person to person, and individual responses to HIV drugs are unique to each individual. body chemistry, liver function and general health can determine whether or not you take enough medication, or too little medication. Therapeutic drug monitoring is a test that determines the quantity of the drug is present in the blood. This can help you with your doctor to determine if you receive too few or too many prescription drugs.

Lipodystrophy

Lipodystrophy is a side effect of drugs against HIV and AIDS, and will impact on men and women quite differently. Lipodystrophy is a general term describing the abnormal accumulation medical or degeneration of adipose tissue of the body (fat) tissue.

Lipodystropy associated with HAART usually see men have more to lose limbs and face. Men also tend to have high cholesterol and triglycerides. the accumulated experience of women more often fat in the breasts and abdomen, and do not suffer the same elevations of cholesterol and triglycerides. This may be due in part to the fact that women often endure shorter HAART, the fact that women accumulate body fat differently from men, and hormonal differences.

A low bone density

Low bone density is another side effect of anti-HIV and HAART. This becomes a bigger problem in women who are survivors of long-term bone density naturally decreases in women with age, or perhaps already there. positive women should have their bone mass checked regularly. The factors mentioned above can lead to early osteoporosis-like symptoms among women, and injuries and diseases associated with it.

Adverse

HIV-positive women report more side effects of HAART more often than men. Nelfinavir and ritonavir have more serious side effects in women. Side effects typical of Nelfinavir include itching and rashes and abdominal pain, moderate to severe, but fewer incidents of diarrhea than ritonavir. On the other hand, women taking ritonavir tend to report more nausea, vomiting, diarrhea, malaise and fatigue. Women living with HIV are also more likely to suffer from rashes than men when taking nevirapine, Atripla, and delavirdine.

It is interesting to note that most regimens are based on data from clinical trials involving sampling dominated by men and testing. This further reinforces the importance of therapeutic drug monitoring to ensure that you take the correct amount of medicine for you.

Very combination antiretroviral can reduce the incidence of opportunistic infections, delay the onset of AIDS, and the lifetime increase. There is little doubt that HAART is beneficial for people living with HIV. There are still many questions unanswered. These drugs are not without potential side effects and long-term toxicity. It is also important to note that membership.